The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop
Abstract
BACKGROUND: Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a debilitating multisystem condition affecting more than 1 million adults in the United States. PURPOSE: To determine benefits and harms of treatments for adults with ME/CFS and identify future research needs. DATA SOURCES: MEDLINE, PsycINFO, and Cochrane databases (January 1988 to September 2014); clinical trial registries; reference lists; and manufacturer information. STUDY SELECTION: English-language randomized trials of the effectiveness and adverse effects of ME/CFS treatments. DATA EXTRACTION: Data on participants, study design, analysis, follow-up, and results were extracted and confirmed. Study quality was dual-rated by using prespecified criteria; discrepancies were resolved through consensus. DATA SYNTHESIS: Among 35 treatment trials enrolling participants primarily meeting the 1994 Centers for Disease Control and Prevention and Oxford case definitions of CFS, the immune modulator rintatolimod improved some measures of exercise performance compared with placebo in 2 trials (low strength of evidence). Trials of galantamine, hydrocortisone, IgG, valganciclovir, isoprinosine, fluoxetine, and various complementary medicines were inconclusive (insufficient evidence). Counseling therapies and graded exercise therapy compared with no treatment, relaxation, or support improved fatigue, function, global improvement, and work impairment in some trials; counseling therapies also improved quality of life (low to moderate strength of evidence). Harms were rarely reported across studies (insufficient evidence). LIMITATION: Trials were heterogeneous and were limited by size, number, duration, applicability, and methodological quality. CONCLUSION: Trials of rintatolimod, counseling therapies, and graded exercise therapy suggest benefit for some patients meeting case definitions for CFS, whereas evidence for other treatments and harms is insufficient. More definitive studies comparing participants meeting different case definitions, including ME, and providing subgroup analysis are needed to fill research gaps.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systematic reviews have shown low strength of evidence for the effectiveness of different complementary therapies [19], cognitive-behavioral therapy (CBT), counseling and behavioral therapies [14,22], and graded exercise therapy [23] for improvement of fatigue, physical functioning, sleep, and quality of life in patients with ME/CFS.”
From Systematic review of mind‐body interventions to treat myalgic encephalomyelitis/chronic fatigue syndrome (2021) · cites this paper as [19]
In the citing paper
“There is no cure for ME/CFS nor any FDA or Health Canada approved medication to treat it [14,19], therefore the focus tends to be on managing and minimizing the symptoms and improving quality of life.”
From Systematic review of mind‐body interventions to treat myalgic encephalomyelitis/chronic fatigue syndrome (2021) · cites this paper as [19]
In the citing paper
“It has long been suspected that the Oxford criteria may therefore fail to exclude individuals with other fatiguing conditions [14,19].”
From Systematic review of mind‐body interventions to treat myalgic encephalomyelitis/chronic fatigue syndrome (2021) · cites this paper as [19]
In the citing paper
“Although some studies indicate an effect by counseling and CBT, results remain inconsistent [19] spurring interest in third-wave cognitive therapies like ACT [20].”
Citations
Cites
The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study
Fukuda, K., Straus, S. E., Hickie, I., Sharpe, M. C., Dobbins, J. G., Komaroff, A., & and International Chronic Fatigue Syndrome Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-12-199412150-00009 · Cited by 4,969
Chronic Fatigue Syndrome: A Working Case Definition
Holmes, G. P., KAPLAN, J. E., GANTZ, N. M., KOMAROFF, A. L., SCHONBERGER, L. B., STRAUS, S. E., Jones, J. F., DUBOIS, R. E., CUNNINGHAM-RUNDLES, C., Pahwa, S. G., et al. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-387 · Cited by 1,713
Myalgic encephalomyelitis: International Consensus Criteria
Carruthers, B. M., van de Sande, M. I., Meirleir, K. L. D., Klimas, N. G., Broderick, G., Mitchell, T., Staines, D., Powles, A. C. P., Speight, N., Vallings, R., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02428.x · Cited by 1,234 · cited 1×
“There is uncertainty regarding the cause of ME/ CFS, whether it is a pathologically discrete syndrome (2, 4), whether ME should be considered a subset of CFS or its own distinct disease (6), and whether symptoms are nonspecific and shared by other disease entities.”
BackgroundCarruthers, B. M., Jain, A. K., De Meirleir, K. L., Peterson, D. L., Klimas, N. G., Lerner, A. M., Bested, A. C., Flor-Henry, P., Joshi, P., Powles, A. C. P., et al. (2003) · Journal of Chronic Fatigue Syndrome · doi:10.1300/j092v11n01_02 · Cited by 1,180
A report—Chronic fatigue syndrome: Guidelines for research
Sharpe, M. C. (1991) · Journal of the Royal Society of Medicine · doi:10.1177/014107689108400224 · Cited by 1,026 · cited 1×
“Trials enrolled predominantly middle-aged women from ME/ CFS specialty clinics; used CFS case definitions, primarily the 1994 CDC (3) or Oxford criteria (56), to determine participant eligibility; had small sample sizes (27 trials had <100 participants); and were conducted in the United States and Western Europe (16).”
MethodWhite, P., Goldsmith, K., Johnson, A., Potts, L., Walwyn, R., DeCesare, J., Baber, H., Burgess, M., Clark, L., Cox, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60096-2 · Cited by 897
Cognitive behaviour therapy for the chronic fatigue syndrome: a randomised controlled trial.
Sharpe, M., Hawton, K., Simkin, S., Surawy, C., Hackmann, A., Klimes, I., Peto, T., Warrell, D., & Seagroatt, V. (1996) · BMJ · doi:10.1136/bmj.312.7022.22 · Cited by 528 · cited 1×
“In some trials, counseling and behavior therapies improved fatigue (8, 38, 39, 41, 43, 46, 48, 62), physical function (Figure 1) (38, 40, 41, 43, 44, 48), quality of life (42, 45), work impairment (38, 48), and the clinical global impression of change scale (38, 48, 59) (low to moderate strength of evidence).”
BackgroundA LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
Hardy, R., & Thompson, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6 · Cited by 522
Interventions for the Treatment and Management of Chronic Fatigue Syndrome: A Systematic Review
Whiting, P., Bagnall, A.-M., Sowden, A. J., Cornell, J. E., Mulrow, C. D., & Ramírez, G. (2001) · JAMA · doi:10.1001/jama.286.11.1360 · Cited by 509
Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial.
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.3.408 · Cited by 491 · cited 1×
“In some trials, counseling and behavior therapies improved fatigue (8, 38, 39, 41, 43, 46, 48, 62), physical function (Figure 1) (38, 40, 41, 43, 44, 48), quality of life (42, 45), work impairment (38, 48), and the clinical global impression of change scale (38, 48, 59) (low to moderate strength of evidence).”
Background
Flagged first, then by citations
Research works printed but not linked: 5
- Jason LA, 2013, Fatigue, 1, 168
- Öckerman PA, 2000, Clin Pract Alternat Med, 1, 88
- Chambers D, 2006, J R Soc Med, 99, 506
- Edmonds M, 2004, Cochrane Database Syst Rev, CD003200
- 10.7326/M15-03577 · DOI
Cited by
Sorted by citations
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
“Abnormal fatigue could correspond to form of chronic fatigue syndrome, in this setting one possible remedy is exercise therapy [30].”
BackgroundLim, E., Ahn, Y., Jang, E.-S., Lee, S., Lee, S., & Son, C. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02269-0 · Cited by 489
“These studies may be promising; however, no therapeutics that can cure CFS/ME or objective diagnostic methods are available yet [13].”
BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Rivera, M. C., Mastronardi, C. A., Silva, C., Arcos‐Burgos, M., & Lidbury, B. A. (2019) · Diagnostics · doi:10.3390/diagnostics9030091 · Cited by 329
“Complementary and alternative medicine Nutritional supplements, Acetyl-l-carnitine, Essential fatty acids, Magnesium, Vitamins, Coenzyme Q10 plus Nutritional supplements may improve ME/CFS-related physical and mental fatigue in patients with specific nutritional deficiencies [215].”
BackgroundTLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 296
“In patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), treatment with the poly-IC12U drug rintatolimod led to an improvement in exercise tolerance and showed dose-sparing effects in a Phase III clinical trial in 2012 [23].”
BackgroundInfluentialKomaroff, A. L., & Lipkin, W. I. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.002 · Cited by 276
“Moreover, controlled studies of the antidepressant fluoxetine in people with ME/CFS have demonstrated no benefit [32].”
The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection
Moghimi, N., Napoli, M. D., Biller, J., Siegler, J. E., Shekhar, R., McCullough, L. D., Harkins, M. S., Hong, E., Alaouieh, D., Mansueto, G., et al. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01130-1 · Cited by 202
Karshikoff, B., Sundelin, T., & Lasselin, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00021 · Cited by 187
“One of the key symptoms is “postexertional fatigue” (64), which, interestingly, appears to be somewhat unique for this patient group (65).”
BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An Overview
Deumer, U.-S., Varesi, A., Floris, V., Savioli, G., Mantovani, E., López-Carrasco, P., Rosati, G. M., Prasad, S., & Ricevuti, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204786 · Cited by 167
“Although different meta-analysis and clinical trials have shown robust evidence in favor of cognitive-behavioral therapy (CBT) and graded exercise therapy (GET) [8–17], more research should be carried out to find advanced therapeutic approaches [6,18].”
BackgroundCastro‐Marrero, J., Sáez‐Francàs, N., Santillo, D., & Alegre, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13702 · Cited by 142
“Drugs such as isoprinosine and rintatolimod have been used in experimental studies of the illness but have not been approved for marketing for any condition in the USA (Smith et al., 2015).”
BackgroundMethodInfluentialESCMID rapid guidelines for assessment and management of long COVID
Yelin, D., Moschopoulos, C. D., Margalit, I., Gkrania‐Klotsas, E., Landi, F., Stahl, J. ‐., & Yahav, D. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.018 · Cited by 145
The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
König, R. S., Albrich, W. C., Kahlert, C. R., Bahr, L. S., Löber, U., Vernazza, P., Scheibenbogen, C., & Forslund, S. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.628741 · Cited by 133
Wormgoor, M. E. A., & Rodenburg, S. C. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02683-4 · Cited by 119
“However, several previous systematic reviews mentioned some uncertainty as to whether findings in studies with Oxford or Fukuda criteria are applicable to ME/CFS patients diagnosed with criteria requiring PEM [33, 35, 37, 44].”
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease
Arron, H. E., Marsh, B. D., Khan, M. A., Jaeger, B., Kell, D., & Pretorius, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386607 · Cited by 127
Importance of fatigue and its measurement in chronic liver disease
Gerber, L. H., Weinstein, A. A., Mehta, R., & Younossi, Z. M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i28.3669 · Cited by 94
Chronic fatigue syndrome: progress and possibilities
Sandler, C. X., & Lloyd, A. R. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50553 · Cited by 74
Zhang, Z.-T., Du, X.-M., Ma, X., Zong, Y., Chen, J., Yu, C., Liu, Y.-G., Chen, Y., Zhao, L.-J., & Lu, G. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0539-1 · Cited by 72
Geraghty, K., Hann, M., & Kurtev, S. (2017) · Journal of Health Psychology · doi:10.1177/1359105317726152 · Cited by 72
Geraghty, K., & Blease, C. R. (2018) · Disability and Rehabilitation · doi:10.1080/09638288.2018.1481149 · Cited by 68
“While another systematic review found inconsistent evidence of modest benefit using CBT versus control treatments and more consistent evidence of benefit using GET [95], it was noted that some trials used broad entry criteria (i.”
ResultMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from?
Toogood, P. L., Clauw, D. J., Phadke, S., & Hoffman, D. L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105465 · Cited by 68
Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID
Seo, J.-W., Kim, S. E., Kim, Y., Kim, E. J., Kim, T., Kim, T., Lee, S. H., Lee, E. J., Lee, J., Seo, Y. B., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2024.0024 · Cited by 78
“Some studies have suggested potential benefits of taking rintatolimod, as well as counseling and graded exercise therapy; however, the evidence is limited [117, 118].”
BackgroundPreliminary Guidelines for the Clinical Evaluation and Management of Long COVID
Kim, Y., Kim, S. E., Kim, T., Yun, K. W., Lee, S. H., Lee, E. J., Seo, J.-W., Jung, Y. H., & Chong, Y. P. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0141 · Cited by 65
“Although some studies have suggested the benefit of rintatolimod, counseling therapy, and step-bystep exercise therapy [114, 115], these studies have limitations in using different fatigue interventions and evaluation methods for the outcome.”
MethodHaider, S., Janowski, A. J., Lesnak, J. B., Hayashi, K., Dailey, D. L., Chimenti, R. L., Frey‐Law, L., Sluka, K. A., & Berardi, G. (2022) · Pain · doi:10.1097/j.pain.0000000000002711 · Cited by 61
The ‘cognitive behavioural model’ of chronic fatigue syndrome: Critique of a flawed model
Geraghty, K., Jason, L. A., Sunnquist, M., Tuller, D., Blease, C., & Adeniji, C. (2019) · Health Psychology Open · doi:10.1177/2055102919838907 · Cited by 56
“A wide range of treatments have been tested on ME/CFS patients, ranging from drug therapies, mainly antidepressants and immunological modulators, to non-pharmacological therapies, predominantly psycho-behavioural therapies (Smith et al., 2015).”
Do graded activity therapies cause harm in chronic fatigue syndrome?
Kindlon, T. (2017) · Journal of Health Psychology · doi:10.1177/1359105317697323 · Cited by 47
“This was a significant improvement over previous trials of CBT and GET, where the reporting of harms has been described as poor (Chambers et al., 2006; Marques et al., 2015; Price et al., 2008; Smith et al., 2015).”
ResultCytokine Inhibition in Patients With Chronic Fatigue Syndrome
Roerink, M. E., Bredie, S. J. H., Heijnen, M., Dinarello, C. A., Knoop, H., & van der Meer, J. W. M. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2391 · Cited by 44
“The only effective treatments are cognitive behavioral therapy and graded exercise therapy (3–5), although a substantial proportion of patients do not improve with these treatments (6).”
BackgroundAcupuncture for chronic fatigue syndrome: a systematic review and meta-analysis
Zhang, Q., Gong, J., Dong, H., Xu, S., Wang, W., & Huang, G.-Y. (2019) · Acupuncture in Medicine · doi:10.1136/acupmed-2017-011582 · Cited by 43
“Acupuncture in Medicine, 37(4) Fi rs t au th or (y ea r) D ia gn os is Pa rt ic ip an ts In te rv en tio ns O ut co m e”
BackgroundInfluentialVink, M., & Vink-Niese, F. (2019) · Diagnostics · doi:10.3390/diagnostics9040124 · Cited by 47
“Systematic reviews by Cairns and Hotopf (2005), Castro-Marrero et al. (2017), Chambers et al. (2006), Malouff et al. (2007), Smith et al. (2015) and Whiting et al. (2001) [10,106,107,178–180], a systematic review and meta-analysis by Marques et al. (2015) [181] and a meta-analysis by Castell et al.…”
BackgroundJoseph, P., Pari, R., Miller, S., Warren, A., Stovall, M. C., Squires, J., Chang, C.-J., Xiao, W., Waxman, A. B., & Systrom, D. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.04.146 · Cited by 44
Cabanas, H., Muraki, K., Eaton-Fitch, N., Staines, D., & Marshall‐Gradisnik, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687806 · Cited by 42
Patient-reported treatment outcomes in ME/CFS and long COVID
Eckey, M., Li, P., Morrison, B., Bergquist, J., Davis, R. W., & Xiao, W. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426874122 · Cited by 35
Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity
Malik, J. A., Kaur, G., & Agrewala, J. N. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127252 · Cited by 34
Metselaar, P. I., Mendoza‐Maldonado, L., Yim, A. Y. F. L., Abarkan, I., Henneman, P., Velde, A. A. T., Schönhuth, A., Bosch, J. A., Kraneveld, A. D., & Lopez‐Rincon, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-83660-9 · Cited by 31
Kavyani, B., Lidbury, B. A., Schloeffel, R., Fisher, P. R., Missailidis, D., Annesley, S. J., Dehhaghi, M., Heng, B., & Guillemin, G. J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04380-5 · Cited by 32
“FMT is the infusion of liquid filtrate faeces from a healthy donor into the gut of a recipient to target microbiota-gut-brain axis [31].”
BackgroundWhite, P. D., Abbey, S. E., Angus, B., Ball, H. A., Buchwald, D., Burness, C. E., Carson, A. J., Chalder, T., Clauw, D. J., Coebergh, J. A., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330463 · Cited by 35
“Smith, 2015 50 21 ‘Trials of rintatolimod, counselling therapies and graded exercise therapy suggest benefit for some patients meeting case definitions for CFS, whereas evidence for other treatments and harms is insufficient.’”
BackgroundLarkin, D., & Martin, C. R. (2017) · Neurophysiologie Clinique · doi:10.1016/j.neucli.2017.01.012 · Cited by 32
“As a consequence of diagnostic challenges and because patients often present with a multitude of symptoms, treatment approaches have been broad and included immunologic, pharmacologic, behavioral treatment and complementary and alternative medicines [57].”
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Real Illness
Komaroff, A. L. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0647 · Cited by 31
“The AHRQ-commissioned review of treatment trials, published in this issue (2), finds that counseling therapies and graded exercise therapy might help improve fatigue and function in some, but not all, patients; that not all trials show a benefit for the average patient; and that neither treatment is curative.”
Khanpour Ardestani, S., Karkhaneh, M., Stein, E., Punja, S., Junqueira, D. R., Kuzmyn, T., Pearson, M., Smith, L., Olson, K., & Vohra, S. (2021) · Medicina · doi:10.3390/medicina57070652 · Cited by 30
“It has long been suspected that the Oxford criteria may therefore fail to exclude individuals with other fatiguing conditions [14,19].”
BackgroundInfluentialAcceptance & Commitment Therapy for ME/CFS (Chronic Fatigue Syndrome) – A feasibility study
Jonsjö, M. A., Wicksell, R. K., Holmström, L., Andreasson, A., & Olsson, G. L. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.02.008 · Cited by 27
Göebel, A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.02.011 · Cited by 28
Kuut, T. A., Buffart, L. M., Braamse, A. M. J., Csorba, I., Bleijenberg, G., Nieuwkerk, P., Moss-Morris, R., Müller, F., & Knoop, H. (2024) · Psychological Medicine · doi:10.1017/s0033291723003148 · Cited by 27
“…2022; Malouff, Thorsteinsson, Rooke, Bhullar, & Schutte, 2008; Marques, De Gucht, Gouveia, Leal, & Maes, 2015; Price, Mitchell, Tidy, & Hunot, 2008; Smith et al., 2015) and one systematic review (Ingman, Smakowski, Goldsmith, & Chalder, 2022), although one meta-analysis revised its decision to…”
Chronic fatigue syndrome in the emergency department
Timbol, C. R., & Baraniuk, J. N. (2019) · Open Access Emergency Medicine · doi:10.2147/oaem.s176843 · Cited by 24
Old muscle in young body: an aphorism describing the Chronic Fatigue Syndrome
Pietrangelo, T., Fulle, S., Coscia, F., Gigliotti, P. V., & Fanò, G. (2018) · European Journal of Translational Myology · doi:10.4081/ejtm.2018.7688 · Cited by 22
Dai, L., Liu, Z., Zhou, W., Zhang, L., Miao, M., Wang, L., Hua, H., Wang, B., & Ji, G. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155636 · Cited by 23
Almenar‐Pérez, E., Sánchez-Fito, T., Ovejero, T., Nathanson, L., & Oltra, E. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030126 · Cited by 22
“as reference papers to evaluate common drug-based ME/CFS therapies [46,47].”
Are ME/CFS Patient Organizations “Militant”?
Blease, C., & Geraghty, K. (2018) · Journal of Bioethical Inquiry · doi:10.1007/s11673-018-9866-5 · Cited by 23
Jonsjö, M. A., Wicksell, R. K., Holmström, L., Andréasson, A., Bilevičiūtė-Ljungar, I., & Olsson, G. (2017) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2017.1287546 · Cited by 19
“The evidence for any effective medical treatment of the condition is weak, despite numerous studies [4].”
BackgroundPediatric chronic fatigue syndrome: current perspectives
Crawley, E. M. (2018) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s126253 · Cited by 21
Robbins, R. C., Helmer, D. A., Monahan, P., Hunt, S. C., McAndrew, L. M., Nazario, M., Brown, W. J., Chao, W., Navarro, A., & Sall, J. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.01.031 · Cited by 20
“Finally, a systematic review found that after exclusion of an outlier, there was evidence that cognitive-behavioral therapy improved physical functioning in ME/CFS compared with control.(15) This finding was supported by 2 subsequent clinical trials for ME/CFS that found evidence for cognitive-behavioral therapy’s imp…”
ResultCognitive remediation training improves performance in patients with chronic fatigue syndrome
McBride, R., Horsfield, S., Sandler, C. X., Cassar, J., Casson, S. M., Cvejic, E., Vollmer-Conna, U. S., & Lloyd, A. R. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.035 · Cited by 20
“Both the CBT/GET and the CET groups also displayed improvement on the self-report symptoms relating to fatigue and to physical and social function status, consistent with previous research (Larun et al., 2015; Sandler et al., 2016; Smith et al., 2015).”
Sun, Y., Zhang, Z., Qiao, Q., Zou, Y., Wang, L., Wang, T., Lou, B., Li, G., Xu, M., Wang, Y., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05710-w · Cited by 19
Kronisk utmattelsessyndrom/myalgisk encefalopati – sykdomsmekanismer, diagnostikk og behandling
Wyller, V. B., Reme, S. E., & Mollnes, T. E. (2015) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.15.1180 · Cited by 18
“With the possible exception of the immunomodulatory drug rintatolimod, a recent systematic review failed to show efficacy of any pharmaceutical therapies for chronic fatigue syndrome/myalgic encephalomyelitis, be it immunoglobulins, hydrocortisone, selective serotonin reuptake inhibitors or antiviral agents (38).”
BackgroundZhang, Y., Jin, F., Wei, X., Jin, Q., Xie, J., Pan, Y., & Shen, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958005 · Cited by 18
Baklund, I. H., Dammen, T., Moum, T. Å., Kristiansen, W., Sosa, D. D., Castro‐Marrero, J., Helland, I. B., & Strand, E. B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143105 · Cited by 18
“No cure or specific treatment exists, nor are there any specific biomarkers [10,11].”
BackgroundSubjective insomnia is associated with low sleep efficiency and fatigue in middle-aged women
Hirose, A., Terauchi, M., Akiyoshi, M., Owa, Y., Kato, K., & Kubota, T. (2016) · Climacteric · doi:10.1080/13697137.2016.1186160 · Cited by 18
Frontera, J. A., Guekht, A. B., Allegri, R., Ashraf, M., Baykan, B. B., Crivelli, L., Easton, A., García‐Azorín, D., Helbok, R., Joshi, J., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120827 · Cited by 17
Categorical interoception and the role of threat
Zacharioudakis, N., Vlemincx, E., & den Bergh, O. V. (2019) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2019.12.009 · Cited by 21
Zhang, Y., & Wang, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1373748 · Cited by 20
Le syndrome de fatigue chronique : une nouvelle maladie ?
de Korwin, J.-D., Chiche, L., Banovic, I., Ghali, A., Delliaux, S., Authier, F., Cozon, G. J. N., Hatron, P., Fornasieri, I., & Morinet, F. (2016) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2016.05.003 · Cited by 16
El-Mokadem, J. F. K., DiMarco, K., Kelley, T. M., & Duffield, L. (2020) · Spirituality in Clinical Practice · doi:10.1037/scp0000232 · Cited by 14
Bijlsma, N., & Cohen, M. M. (2018) · Environmental Health and Preventive Medicine · doi:10.1186/s12199-018-0709-0 · Cited by 14
Ahmed, A., Mewes, J. C., & Vrijhoef, H. J. (2019) · Journal of Health Psychology · doi:10.1177/1359105319847261 · Cited by 14
“In light of the debate around the scientific rigour of studies on therapies for ME/CFS, existing reviews assessing the effectiveness of these therapies (e.g. Larun et al., 2017; Smith et al., 2015) need to be updated, given the main methodological concerns raised more recently.”
BackgroundSchmid, S. R., Uecker, C., Fröhlich, A., & Langhorst, J. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01792-1 · Cited by 13
“According to Smith and colleagues [8] CFS is furthermore defined as a severely debilitating, multisystem disorder that is also characterized by neurological and cognitive changes, motor dysfunction, altered immune response, autonomic responses, persistent deterioration after exertion, and memory or…”
Sapra, A., & Bhandari, P. (2021) · StatPearls · Cited by 13
A reexamination of the cognitive behavioral model of chronic fatigue syndrome
Sunnquist, M., & Jason, L. A. (2018) · Journal of Clinical Psychology · doi:10.1002/jclp.22593 · Cited by 12
Vink, M. (2016) · Journal of Neurology and Neurobiology · doi:10.16966/2379-7150.124 · Cited by 12
“This is in stark contrast to the PACE trial authors’ response to a National Institutes of Health treatment review of ME/CFS [89], in which the PACE trial authors stated, “It is important not to overemphasise the harms associated with an effective treatment when there are so few others available” [90].”
Mansoubi, M., Richards, T., Ainsworth-Wells, M., Fleming, R., Leveridge, P., Shepherd, C., & Dawes, H. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094658 · Cited by 10
Espejo, J., Garcia-Escudero, M., & Oltra, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092673 · Cited by 10
“A more promising option for the treatment of CFS/ME is provided by the CTs using the Toll-like Receptor TLR-3 agonist rintatolimod (Poly I:C(12)U), which activates interferon-induced proteins, showing medically significant improvement in some cohorts of participating patients [22,27].”
MethodLi, Y., Yang, J., Chau, C. I., Shi, J., Chen, X., Hu, H., & Ung, C. O. L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1266803 · Cited by 9
Noble, S., Bonner, C., Hersch, J. K., Jansen, J., McGeechan, K., & McCaffery, K. J. (2018) · Patient Education and Counseling · doi:10.1016/j.pec.2018.10.011 · Cited by 9
McPhee, G., Baldwin, A., Kindlon, T., & Hughes, B. M. (2019) · Journal of Health Psychology · doi:10.1177/1359105319854532 · Cited by 9
Self-Reported Fatigue Predicts Incident Stroke in a General Population
Barlas, G., Luben, R., Neal, S. R., Wareham, N. J., Khaw, K., & Myint, P. K. (2020) · Stroke · doi:10.1161/strokeaha.119.027163 · Cited by 9
“through deprescribing culprit drugs or prescribing drugs such as antidepressants, is likely to be less widely applicable.(41,43) At”
BackgroundPerry, S. E., & Santhouse, A. M. (2016) · Medicine · doi:10.1016/j.mpmed.2016.09.015 · Cited by 9
Mindfulness training for chronic fatigue syndrome: A pilot study
Sollie, K., Næss, E. T., Solhaug, I., & Thimm, J. C. (2017) · Health Psychology Report · doi:10.5114/hpr.2017.65469 · Cited by 8
“However, the effects of pharmacological treatments are small, and the findings about psychological interventions are inconsistent (Smith et al., 2015).”
BackgroundSomatoforme Störungen – somatoforme Belastungsstörung und verwandte Störungen
Kapfhammer, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_74 · Cited by 8
Fauske, L., Bruland, Ø. S., Dahl, A. A., Myklebostad, A., & Rème, S. E. (2021) · Cancers · doi:10.3390/cancers13164076 · Cited by 8
“In terms of tackling chronic fatigue among the general population, cognitive behaviour therapy (CBT) has been documented to offer certain benefits, albeit with only small to moderate effect sizes [3,4].”
BackgroundBack to the Future? Immunoglobulin Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Brownlie, H., & Speight, N. (2021) · Healthcare · doi:10.3390/healthcare9111546 · Cited by 8
“Firstly, the assessed results of the four trials, historically summarised as “mixed” [25], “inconclusive” [26,76], and/or “insufficient” [76].”
ResultMartín, A. D. V., Salazar, A. D., Pérez, I. M. M., & Pérez, S. E. M. (2025) · International journal of exercise science · doi:10.70252/daya4589 · Cited by 7
“5,6 CFS exhibits significant clinical overlap with fibromyalgia, with a global prevalence estimate ranging from 0.5% to 2%, affecting over 17 million individuals worldwide.”
InfluentialDifferences in Symptoms among Black and White Patients with ME/CFS
Jason, L. A., & Torres, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226708 · Cited by 7
“In the literature, patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have been described as being mostly white, upper-class women, but these samples were primarily recruited from clinical and hospital-based settings [4,5].”
BackgroundEriksen, W. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.02.011 · Cited by 6
Comhaire, F. H., & Deslypère, J. P. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109444 · Cited by 6
Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
White, P. D., Clauw, D. J., van der Meer, J. W. M., Moss-Morris, R. E., & Taylor, R. R. (2015) · Annals of Internal Medicine · doi:10.7326/l15-5171 · Cited by 6
Falaguera-Vera, F. J., Garcia-Escudero, M., Bonastre-Férez, J., Zacarés, M., & Oltra, E. (2020) · Preprints.org · doi:10.20944/preprints202009.0264.v1 · Cited by 5
Chronic fatigue syndrome: what is it and how to treat?
Moylan, S., Eyre, H. A., & Berk, M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00475-7 · Cited by 5
Chronic Fatigue Syndrome, Functional Mitochondriopathy, and Enterohepatic Dysfunction.
Bland, J. S. (2017) · Europe PMC (PubMed Central) · Cited by 5
Sleep Disturbances in General Medical Disorders
Chokroverty, S. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6578-6_47 · Cited by 5
Unexpected findings and promoting monocausal claims, a cautionary tale
Copeland, S. M. (2016) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12584 · Cited by 4
Meng, H., & Friedberg, F. (2017) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2017.1343171 · Cited by 4
“have indicated mixed results with great heterogeneity with respect to the beneficial effect of CBT [9,10].”
ResultFalaguera-Vera, F. J., Garcia-Escudero, M., Bonastre-Férez, J., Zacarés, M., & Oltra, E. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17218044 · Cited by 4
McDonald, S., Tan, S. X., Banu, S., van Driel, M., McGree, J. M., Mitchell, G. K., & Nikles, J. (2021) · Patient · doi:10.1007/s40271-021-00540-0 · Cited by 4
Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain
Wang, E. J., Dolomisiewicz, E., Karri, J. V., Tontisirin, N., & Cohen, S. P. (2023) · The Korean journal of pain · doi:10.3344/kjp.23130 · Cited by 4
Review: Exercise therapy reduces fatigue in chronic fatigue syndrome
Denman, A. M. (2016) · Annals of Internal Medicine · doi:10.7326/acpjc-2016-164-10-055 · Cited by 4
Twisk, F. (2018) · Diagnostics · doi:10.3390/diagnostics8020034 · Cited by 4
“The Dutch Health Council did not conduct a review of the research into ME (and CFS), but based their findings and definition of “ME/CFS” on four reviews by others: (1) the IOM report [9], which reviewed CFS [5] studies only and proposed new criteria; (2) a systemic review of diagnostic criteria commissioned by the US…”
The efficacy and safety of moxibustion for chronic fatigue syndrome
Xue, K., Wang, Y., Wang, X., Chen, P.-N., Xiao, C., Fu, J., & Cui, J. (2021) · Medicine · doi:10.1097/md.0000000000025742 · Cited by 3
The effects of traditional Chinese manual therapy (Tuina) for chronic fatigue syndrome
Ren, J., He, T., Zhou, X., Wu, Z., & Kong, L. (2021) · Medicine · doi:10.1097/md.0000000000027700 · Cited by 3
“In order to reduce the severity of symptoms and improve functional status, treatments are mainly based on the clinical symptoms of patients with CFS since the cause of CFS has not been clearly defined.([10,11]) Although patients with CFS can choose to take drugs to relieve fatigue, the trial shows that except for poor…”
Wang, B., Zhang, X., Lu, P., Sun, P., & He, T. (2025) · JMIR Research Protocols · doi:10.2196/65958 · Cited by 3
“However, the efficacy of these treatments remains controversial [16].”
Yang, B., Wang, T., Xiong, K., Ding, X., Zhang, M., Chen, H., Huang, M. X., & Wu, X. (2025) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000180 · Cited by 3
Khakban, I., Jain, S., Gallab, J., Dharmaraj, B. G., Zhou, F., Lokker, C., Abdelkader, W., Zeraatkar, D., & Busse, J. W. (2025) · Journal of Medical Internet Research · doi:10.2196/65087 · Cited by 2
“First, although current evidence supports exercise therapy [77] and CBT [78] for the management of ME/CFS, some patients find these approaches unacceptable.”
Young, J. L., Powell, R. N., Powell, A., Welling, L. L. M., Granata, L. E., & Saal, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368371 · Cited by 2
“These include mild pain relievers, COX-2 inhibitors, non-steroidal anti-inflammatory drugs, antidepressants, and immune modulators (Castro-Marrero et al., 2017; Graves et al., 2024; Smith et al., 2015).”
Perry, S. E. (2020) · Medicine · doi:10.1016/j.mpmed.2020.09.007 · Cited by 2
Rødevand, L. N. (2017) · Scandinavian Psychologist · doi:10.15714/scandpsychol.4.e1 · Cited by 2
Metadata
- Authors
- Smith, M. E. B., Haney, E., McDonagh, M., Pappas, M., Daeges, M., Wasson, N., Fu, R., & Nelson, H. D.
- Affiliations
- Oregon Health & Science University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-06-16
- Volume
- 162
- Issue
- 12
- Pages
- 841-850
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1601664045
- Cited by
- 142
- References
- 68
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 9 · 2023: 7 · 2022: 12 · 2021: 18 · 2020: 10 · 2019: 14 · 2018: 10 · 2017: 18 · 2016: 17 · 2015: 12
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (290201200014I)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- chronic fatigue syndrome, treatment effectiveness, treatment harms, immunomodulators, graded exercise therapy, counseling, complementary therapy, galantamine, cortisol, isoprinosine, valganciclovir, fluoxetine, fatigue, quality of life, case definition
- MeSH terms
- Adult, Complementary Therapies, Antiviral Agents, Counseling, Encephalomyelitis, Exercise Therapy, Humans, Immunologic Factors, Poly I-C, Poly U, Quality of Life, Fatigue Syndrome, Chronic, Cognitive Behavioral Therapy, Myalgia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
